Immunotherapy shows promise for rare cancers in new trial
NCT ID NCT06333314
First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy as the first treatment for people with advanced cancers that have specific genetic markers (dMMR/MSI). The cancers studied are rare types like pancreatic, stomach, and small bowel cancers, but not colorectal or endometrial. About 120 adults will be randomly assigned to receive either dostarlimab or chemo, and those on chemo whose cancer gets worse may switch to dostarlimab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU - Henri Mondor
NOT_YET_RECRUITINGCréteil, France
Contact
-
CHU Jean Minjoz
NOT_YET_RECRUITINGBesançon, France
Contact
-
CHU Morvan
NOT_YET_RECRUITINGBrest, France
Contact
-
CHU de Bordeaux - Hôpital Haut -Lèvêque
NOT_YET_RECRUITINGPessac, France
Contact
-
CHU de Poitiers
NOT_YET_RECRUITINGPoitiers, France
Contact
-
CHU de Rouen
NOT_YET_RECRUITINGRouen, France
Contact
-
CHU de Toulouse Hôpital Rangueil
NOT_YET_RECRUITINGToulouse, France
Contact
-
Centre Eugène Marquis
NOT_YET_RECRUITINGRennes, France
Contact
-
Centre François Baclesse
NOT_YET_RECRUITINGCaen, France
Contact
-
Centre Georges François Leclerc
NOT_YET_RECRUITINGDijon, France
Contact
-
Centre Jean Perrin
NOT_YET_RECRUITINGClermont-Ferrand, France
Contact
-
Centre Léon Bérard
RECRUITINGLyon, France
Contact
-
Gustave Roussy Grand Paris
NOT_YET_RECRUITINGVillejuif, France
Contact
-
Hôpital Saint-Antoine
NOT_YET_RECRUITINGParis, Île-de-France Region, France
Contact
-
Hôpital la Timone
NOT_YET_RECRUITINGMarseille, France
Contact
-
Institut Jean Godinot
NOT_YET_RECRUITINGReims, France
Contact
-
Institut Mutualiste Montsouris
NOT_YET_RECRUITINGParis, France
Contact
-
Institut Paoli Calmettes
NOT_YET_RECRUITINGMarseille, France
Contact
-
Institut de Cancérologie de Lorraine
NOT_YET_RECRUITINGNancy, France
Contact
-
Institut de Cancérologie de l'Ouest
NOT_YET_RECRUITINGAngers, France
Contact
-
Institut de Cancérologie de l'Ouest
NOT_YET_RECRUITINGSaint-Herblain, France
Contact
-
Institut du Cancer Avignon-Provence
NOT_YET_RECRUITINGAvignon, France
Contact
Conditions
Explore the condition pages connected to this study.